Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2

Author： Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Publisher： Humana Press, Inc

ISSN： 1357-0560

Source： Medical Oncology, Vol.27, Iss.3, 2010-09, pp. : 592-599

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

By Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 372-378

Humana Press, Inc

Access to resources Recommend Favorite

Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

By  

Medical Oncology, Vol. 24, Iss. 2, 2007-06 ,pp. : 189-196

Humana Press, Inc

Access to resources Recommend Favorite

Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR

By Rubenstein Marvin  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1212-1218

Humana Press, Inc

Access to resources Recommend Favorite

Bcl-2/bcl-xL Bispecific Antisense Treatment Sensitizes Breast Carcinoma Cells to Doxorubicin, Paclitaxel and Cyclophosphamide

By Simões-Wüst A.P.  

Breast Cancer Research and Treatment, Vol. 76, Iss. 2, 2002-11 ,pp. : 157-166

Springer Publishing Company

Access to resources Recommend Favorite

Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model

By Tsui Paulus   Rubenstein Marvin   Guinan Patrick  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 339-348

Humana Press, Inc

Access to resources Recommend Favorite